Cost-effectiveness of Pre-Exposure Prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study

Authors :: Jan L. Nouwen
Charles A. Boucher
Janneke van de Wijgert
David A. M. C. van de Vijver
Janneke H. van Dijk
Brooke E Nichols
Peter M. A. Sloot
Rob Baltussen
Phil E. Thuma
Virology
Internal Medicine
Medical Microbiology & Infectious Diseases
School of Computer Engineering
Computational Science Lab (IVI, FNWI)
Source :: PLoS One (print), 8(3):e59549. Public Library of Science, PLoS One, 8, PLoS One, 8, 3, PLoS ONE; Vol 8, PLoS ONE, Vol 8, Iss 3, p e59549 (2013), PLoS ONE, 8(3):e59549. Public Library of Science, PLoS ONE
Publication Year :: 2013
Publisher :: Public Library of Science, 2013.
Abstract: Contains fulltext : 118224.pdf (Publisher’s version ) (Open Access) BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact of different PrEP strategies on averting new infections, prevalence, drug resistance and cost-effectiveness in Macha, a rural setting in Zambia. METHODS: A deterministic mathematical model of HIV transmission was constructed using data from the Macha epidemic (antenatal prevalence 7.7%). Antiretroviral therapy is started at CD4

Subjects :: Rural Population
Pediatrics
Non-Clinical Medicine
Epidemiology
Cost effectiveness
Cost-Benefit Analysis
lcsh:Medicine
HIV Infections
Drug resistance
Global Health
Deoxycytidine
Cost Effectiveness
Pre-exposure prophylaxis
0302 clinical medicine
Prevalence
Emtricitabine
030212 general & internal medicine
lcsh:Science
health care economics and organizations
0303 health sciences
education.field_of_study
Multidisciplinary
Engineering::Computer science and engineering::Computer applications::Life and medical sciences [DRNTU]
Cost-effectiveness analysis
Antivirals
Effective primary care and public health Poverty-related infectious diseases [NCEBP 7]
3. Good health
Primary Prevention
HIV epidemiology
Medicine
Infectious diseases
Research Article
medicine.drug
medicine.medical_specialty
Infectious Disease Control
Anti-HIV Agents
Sexual Behavior
HIV prevention
Population
Organophosphonates
Zambia
Viral diseases
Microbiology
Models, Biological
Sensitivity and Specificity
Infectious Disease Epidemiology
03 medical and health sciences
Health Economics
Acquired immunodeficiency syndrome (AIDS)
SDG 3 - Good Health and Well-being
Virology
medicine
Humans
Tenofovir
education
Biology
030306 microbiology
business.industry
Adenine
lcsh:R
HIV
medicine.disease
Quality-adjusted life year
Immunology
HIV-1
lcsh:Q
Infectious Disease Modeling
business

Tools